Journal
JOURNAL OF IMMUNOLOGY
Volume 198, Issue 11, Pages 4205-4209Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1602131
Keywords
-
Categories
Funding
- Association Nationale de la Recherche et de la Technologie doctoral fellowship
- InvivoGen
- Fondation Pierre Berge (Sidaction)
- Harmonizing, Integrating, and Vitalizing European Research on AIDS/HIV (Rationally Designed Therapeutic Vaccine against HIV-1 Based on a Novel Formulation of Nanoparticle-Protected mRNA)
- European Union [241904]
- Advanced Immunization Technologies [280873]
- Wellcome Trust [100326/Z/12/Z] Funding Source: researchfish
Ask authors/readers for more resources
TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8(+) T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
